A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Cancer type: Multiple diagnosis

Phase: I

Principal Investigator: Sørensen Peter Grundtvig

Country: DK

Keywords: Denmark, Herlev, DNA-PK inhibitor, advanced solid tumors, chronic lymphocytic leukemia, phase I, first-in-human, dose escalation, dose expansion, safety profile, tolerability, PK, antitumor activity, maximum tolerated dose, M3814

Status: Completed

Link to